← Issue №14/ week of Oct 4, 2026/Hepatology

Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=350 · Oct 1, 2026 · Liver International · IF 6.7

Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy.

New evidencehepatocellular carcinomasystematic reviewbiomarker
Clinical takeawayConsider initiating PD-1 inhibitors prior to HAIC in uHCC patients receiving lenvatinib-based triple therapy, particularly in HAIC-treated patients.
What it foundPre-LRT PD-1 inhibitors improved overall survival to 34.03 months vs 30.6 months with Post-LRT PD-1 inhibitors (p=0.032) in uHCC patients receiving HAIC combined with lenvatinib and PD-1 inhibitors.
ContextChallenges current practice by suggesting PD-1 inhibitor timing relative to LRT impacts survival, particularly in HAIC-treated uHCC patients compared to Post-LRT PD-1 inhibitors.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

He J … Chen Z · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues